Artivion (NYSE:AORT) Now Covered by JMP Securities

JMP Securities initiated coverage on shares of Artivion (NYSE:AORT) in a research report sent to investors on Wednesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $33.00 price objective on the stock.

A number of other brokerages have also weighed in on AORT. Needham & Company LLC restated a “buy” rating and issued a $30.00 target price on shares of Artivion in a research note on Friday, September 27th. Stifel Nicolaus boosted their target price on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, September 13th. Lake Street Capital increased their price target on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Finally, Oppenheimer upped their price target on Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $30.60.

Artivion Price Performance

NYSE:AORT opened at $26.86 on Wednesday. The company has a quick ratio of 4.04, a current ratio of 5.63 and a debt-to-equity ratio of 1.07. The firm has a market cap of $1.12 billion, a PE ratio of -111.92 and a beta of 1.74. Artivion has a 12 month low of $12.16 and a 12 month high of $29.24. The company’s 50-day moving average price is $25.84 and its two-hundred day moving average price is $24.59.

Artivion (NYSE:AORT) last announced its earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.03 by $0.04. The business had revenue of $98.02 million for the quarter, compared to the consensus estimate of $97.70 million. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. On average, equities analysts anticipate that Artivion will post 0.2 EPS for the current fiscal year.

Insider Activity

In related news, CAO Amy Horton sold 12,430 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total transaction of $325,417.40. Following the completion of the transaction, the chief accounting officer now owns 139,989 shares in the company, valued at approximately $3,664,912.02. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Artivion news, SVP Jean F. Holloway sold 3,167 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $26.55, for a total transaction of $84,083.85. Following the sale, the senior vice president now directly owns 161,932 shares in the company, valued at approximately $4,299,294.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Amy Horton sold 12,430 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the sale, the chief accounting officer now owns 139,989 shares in the company, valued at approximately $3,664,912.02. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 37,109 shares of company stock valued at $951,935 in the last ninety days. 8.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Artivion

Large investors have recently added to or reduced their stakes in the company. First Eagle Investment Management LLC grew its stake in shares of Artivion by 8.1% during the 1st quarter. First Eagle Investment Management LLC now owns 570,242 shares of the company’s stock worth $12,066,000 after acquiring an additional 42,705 shares in the last quarter. Wasatch Advisors LP grew its position in Artivion by 108.8% in the first quarter. Wasatch Advisors LP now owns 1,083,568 shares of the company’s stock valued at $22,928,000 after purchasing an additional 564,549 shares in the last quarter. Vanguard Group Inc. grew its position in Artivion by 1.3% in the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock valued at $56,388,000 after purchasing an additional 33,982 shares in the last quarter. Tidal Investments LLC acquired a new stake in Artivion in the 1st quarter valued at $257,000. Finally, Allspring Global Investments Holdings LLC lifted its position in Artivion by 291.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock worth $118,000 after buying an additional 4,154 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.